Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Review, H1 2016', provides in depth analysis on Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted pipeline therapeutics. 

The report provides comprehensive information on the Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) 
- The report reviews Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Overview 6
Therapeutics Development 7
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under Development by Stage of Development 7
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under Development by Therapy Area 8
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under Development by Indication 9
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under Development by Companies 12
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under Development by Universities/Institutes 14
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Companies Involved in Therapeutics Development 22
Atlantic Healthcare Plc 22
China Medical System Holdings Limited 23
DiNonA Inc. 24
MingSight Pharmaceuticals 25
RXi Pharmaceuticals Corporation 26
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Drug Profiles 27
alicaforsen sodium - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CMS-024 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
DNP-003 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
melittin - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
MS-553 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Peptides to Inhibit Fibrinogen and ICAM-1 for Oncology, Immunology, Cardiovascular, Musculoskeletal and Hematological Disorders - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
RNAi Oligonucleotide to Inhibit ICAM-1 for Retinal Diseases and Cancer - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Dormant Projects 35
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Discontinued Products 36
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Featured News & Press Releases 37
Feb 11, 2016: Atlantic Healthcare starts pivotal Phase 3 trial of Alicaforsen to treat Inflammatory Bowel Disease Pouchitis 37
Jan 28, 2011: CMS Expects To Launch CMS024 For Treatment Of Primary Liver Carcinoma Three Years Ahead Of Plan In 2013 37
Jul 08, 2008: FDA Grants Orphan Drug Designation For Alicaforsen 39
Dec 02, 2004: Isis Pharmaceuticals Announces Phase 3 Clinical Trials Results Of Alicaforsen With Crohn's Disease 39
Dec 02, 2004: Isis Pharmaceuticals Inc. Announces Phase II clinical Trials Of Alicaforsen For Ulcerative Colitis 40
Apr 08, 2003: Isis Pharmaceuticals Initiates Additional Phase II Clinical Trial Of Alicaforsen, ISIS 2302, In Patients With Ulcerative Colitis 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 21
Pipeline by Atlantic Healthcare Plc, H1 2016 22
Pipeline by China Medical System Holdings Limited, H1 2016 23
Pipeline by DiNonA Inc., H1 2016 24
Pipeline by MingSight Pharmaceuticals, H1 2016 25
Pipeline by RXi Pharmaceuticals Corporation, H1 2016 26
Dormant Projects, H1 2016 35
Discontinued Products, H1 2016 36